Debates continue on the therapeutic targeting of the AKT/mTOR axis under conditions associated with aging, neurodegenerative disorders, cancer, and diabetes, and whether the activation or inhibition of mTOR should be taken as a therapeutic approach is currently under investigation. The gene discussed is MTOR; the disease is diabetes mellitus.